Legal & General Group
ANTX icon

Legal & General Group’s AN2 Therapeutics ANTX Stock Holding History

Legal & General Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Buy
+2,576
New +$11.1K ﹤0.01% 3275
2023
Q2 		– Sell
-1,166
Closed -$11.6K – 3416
2023
Q1 		$11.6K Hold
1,166
– – ﹤0.01% 3185
2022
Q4 		$11.1K Buy
1,166
+775
+198% +$10.4K ﹤0.01% 3250
2022
Q3 		$7K Hold
391
– – ﹤0.01% 3372
2022
Q2 		$3K Buy
+391
New +$5.18K ﹤0.01% 3472

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Legal & General Group's ANTX Position: Q2 2026 in Review

Legal & General Group opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 2,576 shares worth $12.4K. The stake represents ﹤0.01% of the portfolio and ranks #3275 among its holdings. This is a return to the name: Legal & General Group previously reported a position in ANTX as recently as Q1 2023.

Legal & General Group first reported a position in ANTX in Q2 2022 and has held it in 5 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Legal & General Group held 2,576 shares of AN2 Therapeutics worth $12.4K as of Q2 2026.
  • AN2 Therapeutics was a new Legal & General Group position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3275 holding.
  • Legal & General Group first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.